Pacific Biosciences of California(US:PACB) ZACKSยท2024-10-16 23:21Company Performance - Pacific Biosciences of California (PACB) closed at $2.06, reflecting a -1.9% change from the previous session, underperforming the S&P 500 which gained 0.47% [1] - Over the past month, PACB shares increased by 12.3%, outperforming the Medical sector which declined by 4.27% and the S&P 500 which rose by 3.48% [2] Upcoming Earnings - The upcoming earnings report for Pacific Biosciences is scheduled for November 7, 2024, with analysts expecting earnings of -$0.20 per share, indicating a year-over-year growth of 25.93% [3] - Revenue is projected to be $41.9 million, down 24.77% from the same quarter last year [3] Full Year Estimates - For the full year, analysts expect earnings of -$0.95 per share and revenue of $168.07 million, representing changes of +14.41% and -16.18% respectively from the previous year [4] Analyst Estimates and Rankings - Recent modifications to analyst estimates for Pacific Biosciences indicate changing business trends, with positive revisions reflecting optimism about the company's profitability [5] - The Zacks Rank system, which evaluates estimate changes, currently ranks Pacific Biosciences at 3 (Hold), with no changes in the consensus EPS estimate over the last 30 days [7] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 94, placing it in the top 38% of over 250 industries [8]